Home > Insider Trading > Filing (0001493152-22-025399)

Filing Details

Accession Number:: 0001493152-22-025399
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-09-08 17:30:34
Reporting Period:: 2022-09-06

Accepted Time:: 2022-09-08 17:30:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1798749	Aerovate Therapeutics Inc.	AVTE	Pharmaceutical Preparations (2834)	831377888

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1869248	T Benjamin Dake	C/O Aerovate Therapeutics, Inc. 930 Winter Street, Suite M-500 Waltham, MA 02451	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-09-06	9,166	$1.74	9,166	No	4	M	Direct
Common Stock	Disposition	2022-09-06	4,422	$17.94	4,744	No	4	S	Direct
Common Stock	Disposition	2022-09-06	4,138	$18.98	606	No	4	S	Direct
Common Stock	Disposition	2022-09-06	606	$19.78	0	No	4	S	Direct
Common Stock	Acquisiton	2022-09-07	8,220	$1.74	8,220	No	4	M	Direct
Common Stock	Disposition	2022-09-07	5	$18.12	3,658	No	4	S	Direct
Common Stock	Disposition	2022-09-07	3,658	$18.42	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2022-09-06	9,166	$0.00	9,166	$1.74
Common Stock	Stock Option (Right to Buy)	Disposition	2022-09-07	8,220	$0.00	8,220	$1.74

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
45,348		2030-09-03	No	4	M	Direct
37,128		2030-09-03	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.56 to $18.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.57 to $19.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.595 to $20.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.32 to $18.32, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.345 to $18.625, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.